Evidence map›Paper›PMID 35617790›Full record

ArticleBioorganic & medicinal chemistry2022

Discovery of honokiol thioethers containing 1,3,4-oxadiazole moieties as potential α-glucosidase and SARS-CoV-2 entry inhibitors.

Ting Xu, Jie-Ru Meng, Wanqing Cheng, Jia-Zheng Liu, Junyan Chu, Qian Zhang, Nannan Ma, Li-Ping Bai, Yong Guo

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioorganic & medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Overcoming Methicillin-ResistantResearch (Washington, D.C.) · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. BioMedicine · 2022
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Ting XuSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, Henan Province, PR China; State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Disease, Macau University of Science and Technology, Taipa, Macau.
Jie-Ru MengState Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Disease, Macau University of Science and Technology, Taipa, Macau.
Wanqing ChengSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, Henan Province, PR China.
Jia-Zheng LiuState Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Disease, Macau University of Science and Technology, Taipa, Macau.
Junyan ChuSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, Henan Province, PR China.
Qian ZhangSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, Henan Province, PR China.
Nannan MaSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, Henan Province, PR China.
Li-Ping BaiState Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Disease, Macau University of Science and Technology, Taipa, Macau. Electronic address: lpbai@must.edu.mo.
Yong GuoSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, Henan Province, PR China. Electronic address: guoyong_122@zzu.edu.cn.
Zhengzhou University · CNMacau University of Science and Technology · MO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Honokiol, isolated from a traditional Chinese medicine (TCM) Magnolia officinalis, is a biphenolic compound with several biological activities. To improve and broaden its biological activity, herein, two series of honokiol thioethers bearing 1,3,4-oxadiazole moieties were prepared and assessed for their α-glucosidase and SARS-CoV-2 entry inhibitory activities. Among all the honokiol thioethers, compound 7l exhibited the strongest α-glucosidase inhibitory effect with an IC

Indexed as

COVID-19 Drug TreatmentSARS-CoV-2Allyl Compoundsalpha-GlucosidasesAngiotensin-Converting Enzyme 2Biphenyl CompoundsHEK293 CellsHumansLignansMolecular Docking SimulationOxadiazolesPhenolsProtein BindingSpike Glycoprotein, CoronavirusSulfides1,3,4-oxadiazoleAllyl Compoundsalpha-GlucosidasesAngiotensin-Converting Enzyme 2Biphenyl CompoundshonokiolLignansOxadiazolesPhenolsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Sulfides1,3,4-OxadiazoleHonokiolSARS-CoV-2 entry inhibitorThioethersα-Glucosidase inhibitor

Identifiers

PMID35617790
PMCPMC9123836
OpenAlexW4281262088

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.